Dr. Raizman, a cornea and cataract specialist at Ophthalmic Consultants of Boston and the New England Eye Center at Tufts Medical Center, has presented today at the American-European-Congress-of-Ophthalmic-Surgery (AECOS) the approach and potential of Tarsier’s TRS01 eye-drops, during the session about pipeline products to replace steroids.
TRS01 is a steroid-free novel therapy, currently investigated in a phase-3 clinical trial, for treating active noninfectious anterior uveitis, including patients with uveitic glaucoma.
More information about the event can be found here.
